Regardless of what happens to the price of Paxlovid once the product is commercialized, a uniquely American situation will emerge in which a person’s access to a potentially life-saving Covid-19 treatment will depend on arbitrary features like insurance status, age, and Medicaid-eligibility.
When Paxlovid Is “Commercialized” In 2023, Patient Access To The Covid-19 Treatment Will Depend On Insurance Status
